Sight Sciences Q2 2022 Earnings Report
Key Takeaways
Sight Sciences reported a 37% increase in revenue to $17.2 million for the second quarter of 2022, driven by growth in both Surgical Glaucoma and Dry Eye segments. Gross margin expanded to 84%. The company is focused on increasing adoption of its OMNI Surgical System and TearCare System, launching the SION surgical instrument, and advancing dry eye initiatives.
Generated $17.2 million in revenue, a 37% increase compared to the prior year period.
Expanded gross margin to 84% versus 82% in the prior year period.
Increased facilities ordering the OMNI Surgical System to 875 and TearCare System facilities to 762.
Maintained excellence in Surgical Glaucoma account retention with a 100% retention rate.
Sight Sciences
Sight Sciences
Sight Sciences Revenue by Segment
Forward Guidance
Sight Sciences projects revenue for the full year 2022 to range from $68 million to $72 million, which represents growth of approximately 39% to 47% compared to 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income